Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
-
Sydney, Australia, May 25, 2026 (GLOBE NEWSWIRE) -- Fixed-term accounts have been a familiar feature of the Australian savings landscape for decades, characterised by a defined investment period, a...
-
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
-
Sydney, Australia, May 22, 2026 (GLOBE NEWSWIRE) -- Australian savers and income-focused investors are navigating an environment of higher interest rates and persistent inflation. On 5 May 2026, the...
-
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic...
-
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients...
-
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...
-
BioNTech SE will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at ASCO 2026.
-
BioNTech SE präsentiert neue klinische Daten und Studienupdates zu Programmen in der spätklinischen Entwicklung sowie zu innovativen Kombinationsprogrammen
-
STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.